Abstract |
Claudin-low breast cancer represents an aggressive molecular subtype that is comprised of mostly triple-negative mammary tumor cells that possess stem cell-like and mesenchymal features. Little is known about the cellular origin and oncogenic drivers that promote claudin-low breast cancer. In this study, we show that persistent oncogenic RAS signaling causes highly metastatic triple-negative mammary tumors in mice. More importantly, the activation of endogenous mutant KRAS and expression of exogenous KRAS specifically in luminal epithelial cells in a continuous and differentiation stage-independent manner induces preneoplastic lesions that evolve into basal-like and claudin-low mammary cancers. Further investigations demonstrate that the continuous signaling of oncogenic RAS, as well as regulators of EMT, play a crucial role in the cellular plasticity and maintenance of the mesenchymal and stem cell characteristics of claudin-low mammary cancer cells.
|
Authors | Patrick D Rädler, Barbara L Wehde, Aleata A Triplett, Hridaya Shrestha, Jonathan H Shepherd, Adam D Pfefferle, Hallgeir Rui, Robert D Cardiff, Charles M Perou, Kay-Uwe Wagner |
Journal | Nature communications
(Nat Commun)
Vol. 12
Issue 1
Pg. 3742
(06 18 2021)
ISSN: 2041-1723 [Electronic] England |
PMID | 34145248
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Claudins
- Hras protein, mouse
- Proto-Oncogene Proteins p21(ras)
|
Topics |
- Animals
- Cell Differentiation
- Cell Line, Tumor
- Claudins
(metabolism)
- Epithelial Cells
(pathology)
- Epithelial-Mesenchymal Transition
(genetics)
- Female
- Gene Expression Regulation, Neoplastic
(genetics)
- Mammary Glands, Animal
(pathology)
- Mammary Neoplasms, Animal
(genetics, pathology)
- Mesenchymal Stem Cells
(metabolism)
- Mice
- Mice, Knockout
- Proto-Oncogene Proteins p21(ras)
(genetics, metabolism)
- Triple Negative Breast Neoplasms
(genetics)
|